Side-effects: latest news

Side-effects resources

Side-effects features

Side-effects in your own words

Side-effects news from aidsmap

More news

Side-effects news selected from other sources

  • Drug that reduces abdominal fat in HIV patients also may reduce fat in liver

    The only drug to receive Food and Drug Administration approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. Massachusetts General Hospital investigators report that six months of daily injections of tesamorelin significantly reduced fat in the liver without affecting glucose metabolism.

    19 July 2014 | Eurekalert Medicine & Health
  • Common HIV Drug May Boost Suicide Risk

    A medication commonly used to treat HIV appears to double the risk that patients will develop suicidal thoughts or take their lives, new research contends. The finding concerns the anti-HIV drug efavirenz, which is marketed as Sustiva.

    02 July 2014 | Web MD
  • Lowering toxicity of new HIV drugs predicted to improve life expectancy

    While bringing new drugs to market is important for increasing life expectancy in younger people with HIV, lowering the toxicity of those drugs may have an even greater health impact on all HIV patients, a University of Pittsburgh Graduate School of Public Health analysis reveals.

    26 June 2014 | EurekAlert
  • In HIV/TB coinfection, raltegravir may be an alternative to efavirenz

    Patients coinfected with HIV and tuberculosis (TB) may benefit from raltegravir as an alternative to efavirenz, new research suggests.

    02 June 2014 | Medscape
  • ART use not linked to advanced kidney disease in 35,000 with HIV

    Neither current nor recent use of tenofovir or any other antiretroviral therapy (ART) predicted advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD) in a study or more than 35,000 adults with HIV infection.

    12 February 2014 | International AIDS Society
  • What ‘Dallas Buyers Club’ got wrong about the AIDS crisis

    'Tis the season for Oscar bait, and this year, "Dallas Buyers Club" looks set to get at least a few nominations. The movie stars Matthew McConaughey as Ron Woodroof, a Dallas man who contracts HIV in 1985, when the diagnosis was a death sentence. But it risks leaving a false impression of that period in the history of HIV/AIDS, and in particular of the role of AZT.

    11 December 2013 | Washington Post
  • Unusual and rare complication described in San Francisco

    Doctors in San Francisco have reported an unusual and rare finding—an apparently harmless but disfiguring condition called cutis verticis gyrata (CVG) on the heads of four HIV-positive men. In CVG, the skin on the head becomes raised in parts and depressed in others, forming ridges and furrows.

    09 December 2013 | CATIE
  • Differing Effects of Low- and High-Fat Meals on New Raltegravir Formulation

    A high-fat meal affected levels of a reformulated raltegravir tablet less than a low-fat meal, according to results of a three-period study in healthy volunteers [1]. One aim of this trial and other ongoing research is to develop a raltegravir formulation that can be dosed once daily.

    30 October 2013 | NATAP
  • Crofelemer effective for severe or PI-related diarrhea in placebo trial

    Crofelemer, a botanically derived agent indicated for symptomatic relief of noninfectious diarrhea in antiretroviral-treated people, proved particularly effective against severe, intransigent diarrhea and protease inhibitor (PI)-related diarrhea in subgroup analyses of a double-blind placebo-controlled trial.

    19 September 2013 | NATAP
  • Switching From Efavirenz to Rilpivirine Combo Quells CNS Side Effects

    Swapping efavirenz-containing Atripla for rilpivirine-containing Complera (Eviplera in Europe) significantly lowered rates of central nervous system (CNS) side effects and sleep disturbances in a 40-person multicenter pilot trial.

    13 September 2013 | NATAP
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.